Thymosin Beta-4 Dosage Chart: 750mcg Loading Protocol

Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino-acid peptide involved in tissue repair, angiogenesis, and cell migration. It's the most abundant actin-sequestering molecule in mammalian cells and the parent molecule of the TB-500 fragment.

Research-context information only. Thymosin beta-4 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

No FDA-approved human dosing exists. Everything below is extrapolated from animal research and community experience. This is not medical advice.

Quick Reference: Community Protocol

Loading phase: 500 mcg to 1 mg daily for 2 weeks to achieve tissue saturation. Maintenance: 500 mcg twice weekly for 2-6 additional weeks. For the full TB-4 profile, vendor pricing, and comparison with TB-500, see our Thymosin Beta-4 peptide page.

Cycling Details

TB-4 uses a two-phase approach: loading then maintenance. The loading phase (2 weeks daily) saturates tissue levels during the acute healing window. TB-4's short plasma half-life (~2 hours) means frequent dosing is needed for consistent tissue-level concentrations.

The maintenance phase (2x weekly) sustains support while reducing peptide consumption. This mirrors tissue repair timelines seen in animal studies — rapid cell migration and angiogenesis in weeks 1-2, followed by ECM remodeling in weeks 3-8 (Malinda et al., 1999).

Typical protocol lengths: Tendon/ligament/muscle injuries: 4-6 weeks. Skin and wound healing: 4-8 weeks. Post-surgical recovery: 6-8 weeks. Chronic inflammatory conditions: 8-12 weeks with cycling.

Routes of Administration

Subcutaneous (most common): For localized injuries, community protocols describe injecting within a few inches of the injury site. For systemic healing, the abdomen or anywhere with subcutaneous fat is used. A 29-31 gauge insulin syringe is commonly cited.

Intramuscular: Used when targeting a specific muscle injury — direct injection into the muscle belly. Less common than subcutaneous.

Peri-lesional: Direct injection around wound sites, used in dermal wound research.

Reconstitution Quick Reference

10 mg vial + 2 mL BAC water = 5 mg/mL. At this concentration, 750 mcg corresponds to 15 units on a standard insulin syringe; 1 mg is 20 units.

Community reconstitution protocols describe swirling gently rather than shaking, refrigerating at 2-8°C, and discarding after 28 days.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? Compare verified vendors on our best thymosin beta-4 sources page, or browse all coupon codes for up to 50% off.

Where These Numbers Come From

Community TB-4 doses are conservatively extrapolated from a large body of animal research, with some reference to human safety data.

Animal Study Doses: Nearly all TB-4 research uses 6 mcg/mouse IP (~0.24 mg/kg). Using standard allometric scaling to a 70 kg human gives a human equivalent of ~17 mg single dose, or ~5-10 mg/week. Community doses (5-10 mg/week loading, 2-5 mg/week maintenance) sit in the conservative middle of this range.

Phase I Human Safety (Ruff et al., 2010): Massive IV doses of 42, 140, 420, and 1,260 mg were well-tolerated in healthy subjects — no dose-limiting toxicity. This was safety testing, not therapeutic dosing.

Key mechanisms: Actin sequestration for cell migration (Mannherz & Huff, 2011), VEGF-driven angiogenesis (Philp et al., 2003), NF-kB suppression for anti-inflammatory effects (Sosne et al., 2007), and Akt survival signaling (Bock-Marquette et al., 2004).

Stacking Protocols

TB-4 + BPC-157 (Popular Healing Stack)

TB-4 + GHK-Cu

TB-4 vs TB-500

For the complete comparison, see TB-4 vs TB-500.

Side Effects & Safety

• Injection site irritation — mild, transient
• Rare mild fatigue — occasional community report
• No hormonal disruption — unlike some peptides
• Phase I human safety — IV doses up to 1,260 mg well-tolerated with no serious adverse events
• No mutagenic or carcinogenic effects in long-term animal studies
• Theoretical angiogenic concern — pro-angiogenic effects raise questions about existing tumors, though no evidence of tumor promotion exists
• No long-term human data at community doses

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once thymosin beta-4 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.